Avidity Biosciences, Inc. RNA
Institutional shares held
119 Million
340K
calls
145K
puts
Total value of holdings
$5.08B
$14.5M
calls
$6.17M
puts
Market Cap
$2.3B
52,127,000
Shares Out.
Institutional ownership
228.67%
# of Institutions
232
We take great care to ensure that the data presented and summarized in this overview for Avidity Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RNA
View all-
Price T Rowe Associates Inc Baltimore, MD10.8MShares$478 Million0.03% of portfolio
-
Janus Henderson Group PLC London, X010.8MShares$476 Million0.16% of portfolio
-
Rtw Investments, LP New York, NY9.62MShares$425 Million4.2% of portfolio
-
Wellington Management Group LLP Boston, MA9.25MShares$409 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.25MShares$409 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$381 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA7.27MShares$321 Million4.51% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.05MShares$311 Million3.65% of portfolio
-
State Street Corp Boston, MA4.2MShares$186 Million0.0% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A63.53MShares$156 Million0.17% of portfolio
Latest Institutional Activity in RNA
Top Purchases
Top Sells
About RNA
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Insider Transactions at RNA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 22
2025
|
Steven George Hughes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,208
-5.38%
|
$88,320
$40.58 P/Share
|
|
Sep 22
2025
|
Steven George Hughes Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,208
+5.1%
|
$22,080
$10.16 P/Share
|
|
Sep 15
2025
|
Steven George Hughes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,542
-3.82%
|
$69,390
$45.41 P/Share
|
|
Sep 15
2025
|
Steven George Hughes Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,542
+3.68%
|
$9,252
$6.57 P/Share
|
|
Sep 15
2025
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
15,000
-13.38%
|
$615,000
$41.41 P/Share
|
|
Sep 15
2025
|
Teresa Mc Carthy Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+11.8%
|
$330,000
$22.34 P/Share
|
|
Sep 11
2025
|
W. Michael Flanagan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,000
-19.96%
|
$760,000
$38.94 P/Share
|
|
Sep 11
2025
|
W. Michael Flanagan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+16.64%
|
$280,000
$14.22 P/Share
|
|
Sep 05
2025
|
Troy Edward Wilson Director |
SELL
Open market or private sale
|
Direct |
29,500
-19.44%
|
$1,475,000
$50.0 P/Share
|
|
Sep 05
2025
|
Troy Edward Wilson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
14,500
+14.73%
|
$174,000
$12.48 P/Share
|
|
Sep 05
2025
|
Sarah Boyce President and CEO |
SELL
Open market or private sale
|
Direct |
50,000
-14.05%
|
$2,450,000
$49.95 P/Share
|
|
Sep 05
2025
|
Sarah Boyce President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+12.32%
|
$50,000
$1.24 P/Share
|
|
Sep 03
2025
|
Eric Mosbrooker Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,563
-10.66%
|
$308,461
$47.07 P/Share
|
|
Sep 03
2025
|
Eric Mosbrooker Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,563
+9.63%
|
$59,067
$9.05 P/Share
|
|
Sep 02
2025
|
Kathleen P. Gallagher Chief Program Officer |
SELL
Open market or private sale
|
Direct |
188
-0.37%
|
$8,836
$47.42 P/Share
|
|
Aug 28
2025
|
Sarah Boyce President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-7.56%
|
$1,225,000
$49.39 P/Share
|
|
Aug 28
2025
|
Sarah Boyce President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+7.03%
|
$25,000
$1.24 P/Share
|
|
Aug 22
2025
|
Steven George Hughes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,208
-5.38%
|
$101,568
$46.4 P/Share
|
|
Aug 22
2025
|
Steven George Hughes Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,208
+5.1%
|
$22,080
$10.16 P/Share
|
|
Aug 15
2025
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
10,000
-9.33%
|
$460,000
$46.56 P/Share
|
Last 12 Months Summary
Buy / Acquisition
1.16M
Shares
From
27
Insiders
| Grant, award, or other acquisition | 351K shares |
|---|---|
| Exercise of conversion of derivative security | 806K shares |
Sell / Disposition
1.16M
Shares
From
11
Insiders
| Open market or private sale | 1.16M shares |
|---|